ARCHIVES

Also in this 8-page issue: NCI advisors approve $15-million set-aside for laboratory testing on “reduced harm” tobacco products.

This article is from The Cancer Letter archive.

Vol. 30 No. 28 | July 9, 2004

Download PDF Visit The Full Archive

Related Articles

ODAC Recommends Femara Campath For FDA Approval.

January 5, 2001

New Protocol Could Improve Survival Of Rare Brain Tumor

October 30, 2009

New Therapeutic Modalities In Testing For Patients With Carcinoid Syndrome

November 28, 2003

Gene Therapy Shows Positive Results In Phase III Trial

July 25, 2008

Excerpts From Potti’s Application to Practice Medicine In South Carolina

December 9, 2011

Chemical, Viral Carcinogenesis Should Not Be Separated: Shimkin

July 14, 1978